Risk factors

Velos Acquisition I is a blank check company with 7,187,500 founder shares held by its initial shareholders. The company has a 24-month completion window to consummate an initial business combination. Risks include potential impacts from global conflicts, U.S. regulatory policy changes under President Trump, and lack of a maximum redemption threshold.

Vera Bradley relies on mall-based retail, Asian and Central American contract manufacturers, and single distribution hubs in Indiana and Mexico. Strategic execution relies heavily on Project Restoration and managing consumer demand shifts in bags and accessories. Activist investor pressure via Fund 1 Investments creates additional operational distraction and strategic uncertainty.

Whitehawk is a preclinical biopharmaceutical company transitioning to a new antibody-drug conjugate pipeline after divesting its sole commercial product, FYARRO. The company faces significant ongoing net losses, relies on external capital to fund operations, and has never tested its ADC product candidates in humans.

TEN Holdings relies heavily on a single customer generating 64.6% of revenue in 2024 and its controlling stockholder, V-Cube, Inc. The company faces intense webcasting competition, reported net losses of $3.0 million in 2024, and is introducing unproven AI features.

zSpace faces going concern doubts with $12.0M in debt and five material weaknesses in internal controls over financial reporting.

Z Squared faces substantial going concern doubt with minimal cash, negative cash flows, and no bank credit lines. Development heavily depends on clinical trials, regulatory approvals, and third-party intellectual property licenses. The company relies on key personnel like CEO David Mehalick and lacks independent market studies for its business plan.

Sabirnetug is the sole candidate, and its success depends on clinical results and approval for Alzheimer’s disease.

HBV pipeline direction is under review by a new leadership team after a 57% workforce reduction, leaving 19 employees.

Clinical and regulatory success hinges on ACR-368, ACR-2316 and the AP3/OncoSignature precision-oncology approach.

Clinical trial outcomes, safety and regulatory approval dominate risks to ADC Therapeutics’ product candidates.

The February 2025 restructuring pauses the limited European vCLAS launch and redirects resources to the FULCRUM-VT US pivotal trial and product redesign.

Power industry services generated 79% of Fiscal 2025 revenue, making large energy-project awards and execution central to results.